NIRSEVIMAB for Respiratory syncytial virus immunisation: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 56 adverse event reports in the FDA FAERS database where NIRSEVIMAB was used for Respiratory syncytial virus immunisation.
Most Reported Side Effects for NIRSEVIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Respiratory syncytial virus bronchiolitis | 87 | 35.2% | 0 | 57 |
| Drug ineffective | 65 | 26.3% | 0 | 53 |
| Respiratory syncytial virus infection | 38 | 15.4% | 0 | 38 |
| Cough | 19 | 7.7% | 0 | 16 |
| Pyrexia | 15 | 6.1% | 0 | 10 |
| Apnoea | 14 | 5.7% | 0 | 6 |
| Bronchiolitis | 14 | 5.7% | 1 | 11 |
| Wheezing | 13 | 5.3% | 0 | 7 |
| Incorrect dose administered | 12 | 4.9% | 0 | 3 |
| Syringe issue | 11 | 4.5% | 0 | 0 |
| Enteral nutrition | 9 | 3.6% | 0 | 9 |
| Bradycardia | 8 | 3.2% | 1 | 6 |
| Hypoxia | 7 | 2.8% | 0 | 7 |
| Respiratory syncytial virus test positive | 7 | 2.8% | 0 | 4 |
| Rhinitis | 7 | 2.8% | 0 | 7 |
Other Indications for NIRSEVIMAB
Antiviral prophylaxis (27)
Immunisation (24)
Prophylaxis (9)
Product used for unknown indication (7)
Respiratory syncytial virus bronchiolitis (7)